Pharma major Dr Reddy’s Laboratories has launched Nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets, in the US market. The drug indicated for preventing or relieving a sudden attack of angina (chest pain).
The Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of approximately $108 million MAT for the 12 months ending in March 2016 according to the IMS Health, said a release from the company. Dr Reddy’s scrip gained 0.28 per cent on the Bombay Stock Exchange on Monday to close at ₹3048.40.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.